# Final Review

**Purpose:** Log the paper's final state after all revisions
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Timestamp:** 2026-01-29T22:34:23.152501
**Response ID:** resp_0e944af047749cc500697bd18527808195b7aa9231767f5018
**Tokens:** 42693 in / 7008 out
**Response SHA256:** e079266033742531

---

## Referee Report (Top General-Interest Journal)

### Summary
The paper studies whether *must-access* PDMP mandates affected state labor-market aggregates (log employment; unemployment rate) using staggered adoption across 46 states (full-exposure years 2013–2021). The main design is Callaway & Sant’Anna (2021) with not-yet-treated controls (preferred) and LAUS state-month (March) outcomes, 2007–2023. The headline result is a precisely estimated null (ATT ≈ 0.004 log points; unemployment −0.24 pp). The paper is careful about modern DiD issues and includes many robustness exercises, but as written it is not yet at the contribution/credibility threshold for AER/QJE/JPE/ReStud/Ecta/AEJ:EP. The main obstacles are (i) the *thin / non-representative never-treated group* and the resulting fragility of clean identification, (ii) the *coarse outcome measure* (state aggregates) which makes the null hard to interpret substantively, (iii) limited engagement with alternative counterfactual construction methods that are specifically designed for “almost everyone treated,” and (iv) a framing that currently reads closer to a careful internal policy memo than a field-shaping general-interest contribution.

Below I give a demanding format check, then methodological and identification critiques, then concrete ways to make the project publishable.

---

# 1. FORMAT CHECK

**Length**
- The PDF excerpt runs to ~69 pages including appendices (last shown page is 69). Main text appears to run to ~46 pages (Conclusion on p. 39; references begin around p. 41; appendix begins p. 46). This clears the “≥25 pages excluding references/appendix” requirement, but the main text is **long for the size of the contribution**; substantial tightening is needed for a top journal.

**References**
- The bibliography is solid on the modern staggered-DiD literature (Callaway–Sant’Anna; Goodman-Bacon; de Chaisemartin & D’Haultfœuille; Sun–Abraham; Roth et al.; Borusyak–Jaravel–Spiess; Arkhangelsky et al.; Xu; Bai). Domain citations include Buchmueller & Carey; Dave et al.; Patrick et al.; Pardo; Fink et al.; Powell/Alpert; etc.
- However, there are **important missing references** for (i) inference with few groups / thin controls, (ii) synthetic control foundations and augmented SC, and (iii) key PDMP mandate mortality/overdose work. See Section 4 below with BibTeX.

**Prose**
- Major sections are written in paragraphs (Intro pp. 2–5; Institutional background pp. 5–8; Results pp. 20–30; Discussion pp. 35–39). Good.
- Some “technical report” repetition: the same null result is restated many times in slightly different form (Abstract; Intro; Results; Conclusion). Tighten.

**Section depth**
- Introduction has 3+ substantive paragraphs (pp. 2–5). Literature/background (Section 2) has depth. Data and empirical strategy are detailed. Results and Discussion have multiple paragraphs each. Pass.

**Figures**
- Figures have axes, labels, and confidence bands. Readability is mixed: several figures use light colors and thin lines that will not reproduce well in grayscale print (Figures 2–6, pp. ~23–27; appendix figures).
- Figure 1 (staggered adoption plot, p. 12) is fine but needs larger fonts and clearer labeling for publication.

**Tables**
- Tables contain real numbers (Tables 1–4, etc.). Standard errors are typically in parentheses. Pass.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard Errors
- Main estimates report SEs (Table 3, p. 22; tables in appendix). Event-study points also list SEs in tables (Tables 6–8). Pass.

### (b) Significance testing
- p-values are reported for headline ATTs (Abstract; Table 3). Pretrend discussion uses pointwise vs uniform inference. Pass.

### (c) Confidence intervals
- 95% CIs are reported for main effects (Abstract; Table 3 notes). Uniform bands are shown for event studies (Figures 2–6). Pass.

### (d) Sample sizes
- N is reported for major tables (Table 3: 850; Table 18 etc.). Pass, but **some robustness results described in text lack a consistent “N, cohorts contributing, years” reporting**; adopt a uniform reporting template.

### (e) DiD with staggered adoption
- The primary estimator is Callaway & Sant’Anna (2021) DR DiD with not-yet-treated controls and an anticipation window (Section 4.2–4.4, pp. 14–18). This is an acceptable modern approach.
- TWFE is presented mainly as a benchmark and discussed with Goodman–Bacon decomposition (Section 4.6 and Table 9). Good.

### (f) RDD
- Not applicable.

**Bottom line on methodology:** The paper *clears* the “unpublishable due to missing inference / naive TWFE” bar. However, **for a top journal the inference/estimation is not yet aligned with the core empirical challenge of the setting: near-universal adoption and a thin never-treated group.** The paper acknowledges this problem, but does not yet deploy the strongest available solutions (synthetic DiD / augmented synthetic control / interactive fixed effects / randomization inference for thin controls). That is the key gap.

---

# 3. IDENTIFICATION STRATEGY

### Credibility of identification
This is where the paper currently struggles relative to general-interest standards.

**Core issue: “almost everyone treated.”**
- Only four states are never-treated (KS, MO, NE, SD). You correctly show that using them produces pretrend violations for log employment (Figure 2 and Table 5; p. 23–24).
- You then prefer not-yet-treated controls (Figure 3; Table 7), which improves pretrends for log employment.

**But not-yet-treated is not a free lunch in this application.**
- With staggered adoption driven by opioid crisis intensity and policy capacity, “not-yet-treated” states may be on systematically different trajectories (selection on timing). Event-study pretrends help, but with state aggregates and large shocks (Great Recession aftermath; shale boom; ACA; COVID), **failing to reject pretrends is not strong evidence of parallel trends**.
- You partially address this with HonestDiD (Figure 8), which is good practice, but you apply it only to a narrow target (ATT at e=0). For a top journal, I would expect a deeper sensitivity analysis and/or designs that *reduce reliance* on parallel trends with thin/selected controls.

### Treatment definition and partial exposure
- You define “full-exposure year” and use March LAUS outcomes to reduce within-year contamination (Section 3.1–3.2, pp. 8–10). This is thoughtful, but it introduces:
  1. **Measurement noise**: one month may be idiosyncratic.
  2. **Remaining partial exposure** in e = −1 for some states (you exclude via anticipation=1). Still, this is a coding choice that can materially change dynamic profiles.
- Top-journal expectation: show robustness to (i) annual averages, (ii) alternative months, (iii) “effective-date” coding with fractional exposure, and (iv) dropping adoption years entirely (donut/hole around adoption).

### Placebos and robustness
You include:
- TWFE with policy controls (Table 10),
- Goodman–Bacon decomposition (Table 9),
- BJS imputation estimator (Figure 9; Table 19),
- placebo timing shift (Table 20),
- leave-one-out,
- pre-COVID subsample (Table 18),
- HonestDiD sensitivity (Figure 8).

This is a strong menu. **But the robustness does not yet confront the most relevant alternative counterfactual constructions for “few controls”:**
- Synthetic DiD (Arkhangelsky et al. 2021) is cited but not implemented for the main outcome.
- Augmented synthetic control (Ben-Michael, Feller, Rothstein 2021) is not used.
- Generalized synthetic control / interactive fixed effects (Xu 2017; Bai 2009) is cited but not deployed as a primary sensitivity check.
- Inference methods tailored to few control groups are not used (see below).

### Inference with few controls / thin comparison group
Even though the preferred spec uses not-yet-treated controls (so “controls” are more numerous early on), the design still has thin effective controls for late event times and relies heavily on timing comparisons. For the never-treated spec, **the effective number of control clusters is 4**, which makes conventional cluster-robust inference unreliable. A top journal will expect:
- **Randomization inference / permutation inference** (e.g., assign placebo adoption dates and recompute the estimator).
- **Conley–Taber-style** inference or other approaches designed for few groups.
- **Wild cluster bootstrap** variants (and a discussion of why multiplier bootstrap is appropriate in this specific “4-state never treated” case).

### Do conclusions follow from evidence?
- The conclusion “no detectable aggregate employment effects” is supported by the estimates as stated.
- However, the interpretation leans heavily on MDE arguments (Abstract; Section 5.2; Table 17). This is directionally helpful, but **the MDE calculation is simplistic** (SE×(z’s)) and does not fully match the staggered DiD design with varying comparison sets across time. For a top journal, I would want either:
  - design-consistent power simulations, or
  - detectable effect bounds that incorporate the effective number of comparisons at each horizon.

### Limitations
- You acknowledge dilution, substitution, heterogeneity, and COVID (Section 7). Good.
- But the limitation that matters most for publication is: **the paper’s main outcome is arguably too aggregated and too far down the causal chain to be a persuasive target for a state-policy DiD with near-universal adoption.** A top journal will ask: why should we learn about employment from this policy using this design?

---

# 4. LITERATURE (MISSING REFERENCES + BibTeX)

You cite much of the modern DiD set and several PDMP papers, but you are missing several references that are directly relevant to your *thin-control* setting and PDMP mandate impacts.

## (A) Inference with few groups / policy evaluation with few controls
1) **Conley & Taber (2011)** — classic inference when there are few treated/control groups in DiD-like settings. Highly relevant given the 4 never-treated states and the broader thin-control issue.
```bibtex
@article{ConleyTaber2011,
  author  = {Conley, Timothy G. and Taber, Christopher R.},
  title   = {Inference with {D}ifference in {D}ifferences with a Small Number of Policy Changes},
  journal = {Review of Economics and Statistics},
  year    = {2011},
  volume  = {93},
  number  = {1},
  pages   = {113--125}
}
```

2) **Ferman & Pinto (2019)** — improves inference and discusses placebo-style tests in DiD with few treated groups; relevant to your placebo and thin-control concerns.
```bibtex
@article{FermanPinto2019,
  author  = {Ferman, Bruno and Pinto, Cristine},
  title   = {Inference in Differences-in-Differences with Few Treated Groups and Heteroskedasticity},
  journal = {Review of Economics and Statistics},
  year    = {2019},
  volume  = {101},
  number  = {3},
  pages   = {452--467}
}
```

## (B) Synthetic control foundations / augmented SC (natural for near-universal adoption)
Even though you cite synthetic DiD, you should anchor it in the synthetic control tradition and show you understand why these methods were developed.
1) **Abadie & Gardeazabal (2003)** and **Abadie, Diamond & Hainmueller (2010)** (foundational synthetic control).
```bibtex
@article{AbadieGardeazabal2003,
  author  = {Abadie, Alberto and Gardeazabal, Javier},
  title   = {The Economic Costs of Conflict: A Case Study of the Basque Country},
  journal = {American Economic Review},
  year    = {2003},
  volume  = {93},
  number  = {1},
  pages   = {113--132}
}
```
```bibtex
@article{AbadieDiamondHainmueller2010,
  author  = {Abadie, Alberto and Diamond, Alexis and Hainmueller, Jens},
  title   = {Synthetic Control Methods for Comparative Case Studies: Estimating the Effect of California's Tobacco Control Program},
  journal = {Journal of the American Statistical Association},
  year    = {2010},
  volume  = {105},
  number  = {490},
  pages   = {493--505}
}
```

2) **Ben-Michael, Feller & Rothstein (2021)** — augmented synthetic control; extremely relevant as a robustness method with many predictors and limited controls.
```bibtex
@article{BenMichaelFellerRothstein2021,
  author  = {Ben-Michael, Eli and Feller, Avi and Rothstein, Jesse},
  title   = {The Augmented Synthetic Control Method},
  journal = {Journal of the American Statistical Association},
  year    = {2021},
  volume  = {116},
  number  = {536},
  pages   = {1789--1803}
}
```

## (C) PDMP mandates and mortality/overdose outcomes (closely related empirical domain)
You cite Patrick et al. (2016) and systematic reviews, but you should cite prominent econ/health-econ work directly on mandatory PDMPs and overdoses:
1) **Schnell (2018)** — often-cited paper on mandatory PDMPs and opioid overdoses.
```bibtex
@article{Schnell2018,
  author  = {Schnell, Molly},
  title   = {Physician Behavior in the Presence of a Prescription Drug Monitoring Program: Evidence from Mandatory Access Laws},
  journal = {American Economic Journal: Economic Policy},
  year    = {2018},
  volume  = {10},
  number  = {4},
  pages   = {1--36}
}
```
*(If your coding of Schnell’s exact title/journal details differs, correct accordingly—but some version of this citation belongs here.)*

## (D) Positioning relative to “opioids and labor markets”
You have Harris et al. (2020), Borgschulte et al. (2022), Krueger (2017). Consider also citing:
- papers on disability, labor force exit, and opioids beyond Krueger; and
- papers on the 2016 CDC guideline as a national shock interacting with state policy capacity.

(You can add these once you decide the sharper framing—see Section 6.)

---

# 5. WRITING QUALITY (CRITICAL)

### Prose vs bullets
- Pass: Intro/Results/Discussion are paragraph-based.

### Narrative flow / framing
- The motivating question is clear (p. 2), but the narrative currently **overpromises** relative to what the design can deliver. The paper asks: “Can supply-side drug policies reverse labor market damage?” That is a big question. But your actual estimand is: **reduced-form effect of must-access PDMP mandates on state aggregate employment/unemployment**. Those are not the same.
- Recommendation: narrow the claim in the opening paragraphs. A top journal will punish “big question → small reduced form with diluted outcomes” unless the paper offers an unusually credible design or a novel dataset.

### Sentence-level quality
- Generally clear, but too long and repetitive. Many paragraphs restate the same null with slightly different words (Abstract; Intro; Results; Conclusion).
- Suggested rewrite approach: tighten the paper by ~25–35% in main text; move institutional background detail to appendix; make the empirical contribution and identification challenges the centerpiece.

### Accessibility
- Econometric terms are usually defined (CS estimator, DR, anticipation). Good.
- However, the key methodological tension—**what not-yet-treated controls buy you and what they cost you**—needs a simpler explanation early (end of p. 3 or start of Section 4), not primarily later in robustness.

### Figures and tables as stand-alone objects
- Many are close, but not yet publication quality:
  - fonts too small,
  - low-contrast color palettes,
  - event-study plots need consistent y-axis scales across control-group versions to facilitate visual comparison,
  - figure notes are long and partially redundant with text.

---

# 6. CONSTRUCTIVE SUGGESTIONS (HOW TO MAKE THIS PUBLISHABLE)

If you want a credible shot at AEJ:EP (or a general-interest field slot), you likely need to **change what the paper delivers**, not just polish.

## A. Upgrade the design for “near-universal adoption”
1) **Make Synthetic DiD (Arkhangelsky et al. 2021) a primary estimator**, not a cited alternative. This is arguably the method designed for your setting: many treated units, few clean controls, and the need to reweight units/time.
2) Add **Augmented Synthetic Control** as a robustness check.
3) Add **randomization inference / permutation tests** for the sharp null on aggregates: randomly reassign adoption years (respecting adoption-year distribution) and show your estimate is typical under the null.
4) Consider a **border-county design** (you mention it in Section 8 but do not do it). Even if mandates are near-universal, border designs around adoption years can be credible for early years. Use QCEW county employment (workplace-based, high precision) and restrict to counties within X miles of borders.

## B. Move closer to labor-market mechanisms (reduce dilution)
State total employment is extremely blunt. To detect plausible effects, you need outcomes where the signal-to-noise ratio is higher:
- **Employment-to-population ratio** (requires population denominators; can be built from CPS/ACS).
- **Prime-age LFPR** (CPS/ACS).
- **Disability insurance applications/recipiency** (SSA administrative aggregates).
- **Industry employment** in high-injury/high-opioid sectors (construction, mining, manufacturing) using QCEW.
- **Earnings** (QCEW wage data, or BEA).

A top-journal referee will say: if the mechanism runs through opioid dependence among a small share of workers, you should either (i) focus on those subpopulations/sectors, or (ii) admit the aggregate estimand is close to uninformative.

## C. Treatment heterogeneity: mandate “strength” is not optional
Right now treatment is a 0/1 “must-access” indicator, but mandates differ drastically (initial vs every Rx, schedule coverage, delegate access, enforcement, EHR integration, exemptions). You acknowledge this (Section 7.3) but do not exploit it.
- Build a **mandate-strength index** from PDAPS dimensions.
- Estimate **dose-response** effects (CS with continuous/binned treatment intensity, or event studies by strength terciles).
- At minimum, show results for “strong mandates” only, with a transparent definition.

## D. Timing and measurement robustness
- Show robustness to using **annual averages** of LAUS outcomes (and maybe seasonally adjusted series).
- Show robustness to alternative months (January/June/September) or averaging multiple months to reduce noise.
- Implement a **donut** around adoption (drop the −1/0 years entirely) to address partial exposure and implementation ramp-up.

## E. Clarify what can be learned from a null
Your MDE discussion is a good start, but for publication you need sharper interpretation:
- Provide a **back-of-the-envelope mapping** from plausible individual effects → implied aggregate effects using realistic exposure rates (opioid prescribing prevalence among employed, fraction at risk of OUD, etc.).
- Then explicitly state whether your design meaningfully constrains policy-relevant magnitudes.

## F. Reframe the contribution
Right now the selling point is “a careful null.” That can publish in AEJ:EP **if** the design is unusually credible and/or the null resolves a policy debate. To get there:
- Define the policy claim you are adjudicating (e.g., “PDMP mandates will improve labor markets”).
- Show that influential reports/policymakers asserted this.
- Then show your design *can* reject effects of the magnitude implicitly claimed.

---

# 7. OVERALL ASSESSMENT

### Strengths
- Uses modern staggered DiD (CS DR) and explicitly addresses TWFE pitfalls (Sections 4–6).
- Transparent about the thin never-treated issue; shows event-study diagnostics with uniform bands (Figures 2–3).
- Robustness menu is broader than typical applied work (HonestDiD; BJS; placebo timing; pre-COVID).
- Good data construction transparency and clear tables.

### Critical weaknesses (why a top journal would not accept now)
1) **Identification remains fragile in the “almost all treated” environment.** Preferring not-yet-treated controls helps, but does not fully solve selection-on-timing and thin-control credibility problems. You cite but do not deploy the most relevant estimators (synthetic DiD/ASC as main).
2) **Outcome is too aggregated** relative to the plausible mechanism; the null is likely a mechanical consequence of dilution and noise. Without sharper subpopulation/sector outcomes, the result risks being “precisely uninformative.”
3) **Treatment heterogeneity is ignored** in estimation (0/1 mandate), despite being central in the PDMP literature and acknowledged by you as a limitation.
4) **Inference for the never-treated spec** is not convincingly tailored to 4 control clusters; the thin-control results should either be deprioritized further or accompanied by appropriate few-cluster inference.
5) **Writing and framing**: too long, repetitive, and slightly misaligned (big motivating question vs narrow estimand).

### Specific actionable fixes
- Make synthetic DiD and/or augmented synthetic control core.
- Add border-county QCEW design or CPS/ACS subgroup outcomes.
- Construct mandate-strength measures.
- Add few-cluster inference (Conley–Taber / randomization inference).
- Tighten main text substantially and refocus on a crisp policy claim.

---

DECISION: REJECT AND RESUBMIT